The use of chelated radionuclide (samarium-153- ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4241-4249

  Chakraborty, Mala ^a   Wansley, Elizabeth K ^a   Carrasquillo, Jorge A ^d   Yu, Sarah ^b   Paik, Chang H ^b   Camphausen, Kevin ^a   Becker, Michael D ^c   Goeckeler, William F ^c   Schlom, Jeffrey ^a,b   Hodge, James W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Cytogen Corporation   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LEXIDRONAM SAMARIUM SM 153; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE; SAMARIUM; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL STRAIN LNCAP; CHELATION THERAPY; CONTROLLED STUDY; DOSIMETRY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LUNG CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE; TUMOR IMMUNITY; UPREGULATION; BREAST TUMOR; CELL SEPARATION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; PHENOTYPE; PROSTATE TUMOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; PROSTATIC NEOPLASMS; RADIOISOTOPES; SAMARIUM; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 48249149168     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0335     Document Type: Article

References (53)

1. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
2. Chakraborty M, Abrams SI. Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64: 4328-37
3. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80.
4. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
5. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006;12:1897-905.
6. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
7. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991; 27:1084-6.
8. Crespo A, Sureda M, Vazquez B, et al. Bone-targeted therapy in advanced androgen-independent prostate carcinoma: a feasibility study. ASCO Annual Meeting Proceedings 2005;451s (Abstract).
9. Sartor AO, Reid R, Higano C, Bushnell D, Quick D. Repeated dose samarium 153 lexidronam in patients with prostate cancer bone metastases. ASCO Annual Meeting Proceedings 2005:411s (Abstract).
10. Collins C, Eary JF, Donaldson G, et al. Samarium-153 -EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-44.
11. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-96.
12. Alberts AS, Smit BJ, Louw WK, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175-9.
13. Sartor O, Reid RH, Bushnell DL. Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637-43.
14. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.
15. Resche I, Chatal JF, Pecking A, et al. A dosecontrolled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91.
16. Goel A, Dispenzieri A, Greipp PR, et al. PS-341 -mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005; 33:784-95.
17. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with (153)Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34: 1023-30
18. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1: S171-8.
19. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 2002;8: 41-53.
20. Muraro R, Wunderlich D. Thor A, et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985;45:5769-80.
21. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
22. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439-49.
23. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxicT-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004; 10:2139-49.
24. Peng B, Hodge DR, Thomas SB, et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells. J Biol Chem 2005;280: 4182-7.
25. Sobel RE, Sadar MD Cell lines used in prostate cancer research: a compendium of old and new lines - part 2. J Urol 2005;173:360-72.
26. Houle B, Rochette-Egly C, Bradley WE. Tumorsuppressive effect of the retinoic acid receptor (J in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A 1993;90:985-9.
27. Fritah A, Saucier C, DeWever O, et al. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 2008;28:1114-23.
28. Yates CC, Shepard CR, Stolz DB, Wells A. Coculturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007;96:1246-52.
29. Kojima H, Shinohara N, Hanaoka S, et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxicT lymphocytes. Immunity 1994;1: 357-64.
30. + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004;11: 665-80
31. Zamai L, Rana R, Mazzotti G, et al Lymphocyte binding to K562 cells: effect of target-cell irradiation and correlation with ICAM-1 and LFA-3 expression Eur J Histochem 1994;38 Suppl 1:53-60.
32. Uzendoski K, Kantor JA, Abrams SI, Schlom J. Hodge JW. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997:8 851-60.
33. Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biol 2003;24:32-9.
34. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 1999;48:382-5.
35. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195:346-55
36. Garcia-Lora A, Algarra I, Collado A, Garrido F Tumour immunology, vaccination and escape strategies. EurJ Immunogenet 2003;30:177-83
37. Bubenik J. Tumour MHC class I down-regulation and immunotherapy (Review). Oncol Rep 2003;10: 2005-8.
38. French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semm Cancer Biol 2002;12:51-5
39. Reits EA, Hodge JW. Herberts CA, et al Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203: 1259-71.
40. Anderson PM, Wiseman GA, Erlandson L, et al Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005;11:6895-900.
41. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30:649-58.
42. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005;11: 2416-26.
43. We48er J, Sondak VK, Scotland R. et al Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma Cancer 2003;97:186-200.
44. Disis ML, GooleyTA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
45. Schut IC, Waterfall PM, Ross M, et al. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue. BJU Int 2003;91:278-83
46. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
47. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis Ml. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostatespecific antigen expression in prostate cancer. Clin Cancer Res 2001;7:1533-8.
48. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000;13:1186-91.
49. Zhang S, Zhang HS, ReuterVE, et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
50. Yamamoto S, ItoT, Akiyama A, et al. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. Int J Urol 2001;8:374-9.
51. Kass ES, Greiner JW, Kantor JA, et al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 2002;62:5049-57.
52. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34: 646-53.
53. Steffens J, Friedmann W, Lobeck H. Immunohistochemical demonstration of tumor-associated antigens with the aid of monoclonal and polyclonal antisera in carcinoma of the bladder. Urol Res 1985; 13:55-9.